Preoperative GLP-1 receptor agonist use was not associated with postoperative weight loss differences in bariatric surgery patients, including those with type 2 diabetes.
Does preoperative GLP-1 receptor agonist use affect postoperative weight loss in patients undergoing bariatric surgery?
Preoperative GLP-1 therapy does not appear to compromise weight loss outcomes following metabolic and bariatric surgery.
Absolute Event Rate: 0% vs 0%
Preoperative GLP-1 use was not associated with postoperative weight loss in a statewide, multi-system cohort, including in an active-comparator analysis among patients with type 2 diabetes. These findings suggest preoperative GLP-1 therapy is unlikely to compromise MBS weight loss outcomes.
Holler et al. (Tue,) reported a other. Preoperative GLP-1 receptor agonist use was not associated with postoperative weight loss differences in bariatric surgery patients, including those with type 2 diabetes.